Table 1.

SARS-CoV-2 VOC and VOI RBD mutations on ACE2 or bamlanivimab affinity.

Variant category	Variants (nomenclature)	Mutations in RBD region	ACE2 affinity change versus ancestral RBD	Bamlanivimab affinity change versus ancestral RBD
Variant of concern (VOC)	Alpha	N501Y	10-fold increase	No change
	Beta	K417N E484K N501Y	2-fold increase	E484K abolishes mAb binding
	Gamma	K417T E484K N501Y	5-fold increase	E484K abolishes mAb binding
	Delta	L452R T478K	2-fold increase	L452R decreases mAb by 20-fold
	Omicron	G339D S371L S373P S375F K417N N440K G446S S477N T478K E484A Q493K G496S Q498R N501Y Y505H	Potential increase due to N501Y mutation and/or other ACE2 contact residue mutations	E484A abolishes mAb binding
Variant of interest (VOI)	Lambda	L452Q F490S	No change	L452Q decreases mAb by 8-fold F490S decreases mAb by 20-fold
	Mu	R346K E484K N501Y	9-fold increase	E484K abolishes mAb binding